GB 251
Alternative Names: GB-251; NBT-828Latest Information Update: 20 Jun 2022
At a glance
- Originator NewBio Therapeutics
- Developer Genor Biopharma
- Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Breast cancer
Most Recent Events
- 20 Jun 2022 Phase-I clinical trials in Breast cancer (Second-line therapy or greater, Metastatic disease) in China (Parenteral) (Genor Biopharma pipeline; June 2022)
- 01 Nov 2021 Phase-I clinical trials in Breast cancer in China (Parenteral) (NewBio therapeutics pipeline, November 2021)
- 01 Jul 2020 GB 251 is still in preclinical trials in China